175739-42-1

Basic information

• Product Name: 6-benzyl-1-[(benzyloxy)methyl]-5-(propan-2-yl)pyrimidine-2,4(1H,3H)-dione
• CAS NO: 175739-42-1
• Molecular Formula: C₂₂H₂₄N₂O₃
• Molecular Weight: 364.4376
• Mol File: 175739-42-1.mol

Chemical Properties

• Density: 1.172g/cm³
• Refractive Index: 1.582
• CAS DataBase Reference: 6-benzyl-1-[(benzyloxy)methyl]-5-(propan-2-yl)pyrimidine-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 6-benzyl-1-[(benzyloxy)methyl]-5-(propan-2-yl)pyrimidine-2,4(1H,3H)-dione(175739-42-1)
• EPA Substance Registry System: 6-benzyl-1-[(benzyloxy)methyl]-5-(propan-2-yl)pyrimidine-2,4(1H,3H)-dione(175739-42-1)

Safety Data

• Hazardous Substances Data: 175739-42-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
BzPMPD is utilized as a precursor in the development of new pharmaceutical drugs, leveraging its potential pharmacological properties for the treatment of various conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, BzPMPD is employed as a subject of study for its anti-inflammatory and anti-hypertensive properties, with the aim of discovering new therapeutic agents.
Used in Drug Synthesis:
BzPMPD serves as a key intermediate in the synthesis of various drug molecules, contributing to the advancement of pharmaceutical formulations.
Used in Biochemical Studies:
6-benzyl-1-[(benzyloxy)methyl]-5-(propan-2-yl)pyrimidine-2,4(1H,3H)-dione is also used in biochemical research to understand its interactions with biological systems, potentially leading to insights into new mechanisms of action for treating diseases.
Used in Drug Delivery Systems:
BzPMPD may be incorporated into drug delivery systems to enhance the bioavailability and therapeutic efficacy of associated pharmaceuticals, particularly in conditions where its anti-inflammatory or anti-hypertensive properties could be beneficial.

Upstream product

• 718-08-1 ethyl 3-oxo-4-phenylbutyrate 
• 103-80-0 phenylacetyl chloride 
• 199851-91-7 6-benzyl-5-isopropyl-2-thiouracil 
• 100-51-6 benzyl alcohol 
• 140-29-4 phenylacetonitrile 
• 176519-53-2 ethyl 2-isopropyl-3-oxo-4-phenylbutanoate 
• 3587-60-8 Benzyloxymethyl chloride 
• 176519-55-4 6-benzyl-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 609-12-1 ethyl 2-bromoisovalerate 

Relevant articles and documents

New efficient and flexible synthetic route to Emivirine and its analogs

A revised synthetic route to Emivirine (MKC-442) via properly substituted β-keto ester converted from Meldrum's Acid was developed. This method could be applied to the synthesis of a variety of MKC-442 analogues and open the way for their systematic biological evaluation.

N-3 hydroxylation of pyrimidine-2,4-diones yields dual inhibitors of HIV reverse transcriptase and integrase

A new molecular scaffold featuring an N-hydroxyimide functionality and capable of inhibiting both reverse transcriptase (RT) and integrase (IN) of human immunodeficiency virus (HIV) was rationally designed based on 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) non-nucleoside RT inhibitors (NNRTIs). The design involves a minimal 3-N hydroxylation of the pyrimidine ring of HEPT compound to yield a chelating triad which, along with the existing benzyl group, appeared to satisfy major structural requirements for IN binding. In the mean time, this chemical modification did not severely compromise the compound's ability to inhibit RT. A preliminary structure-activity relationship (SAR) study reveals that this N-3 OH is essential for IN inhibition and that the benzyl group on N-1 side chain is more important for IN binding than the one on C-6.

3-Hydroxypyrimidine-2,4-diones as an Inhibitor Scaffold of HIV Integrase

Integrase (IN) represents a clinically validated target for the development of antivirals against human immunodeficiency virus (HIV). Inhibitors with a novel structure core are essential for combating resistance associated with known IN inhibitors (INIs). We have previously disclosed a novel dual inhibitor scaffold of HIV IN and reverse transcriptase (RT). Here we report the complete structure-activity relationship (SAR), molecular modeling, and resistance profile of this inhibitor type on IN inhibition. These studies support an antiviral mechanism of dual inhibition against both IN and RT and validate 3-hydroxypyrimidine-2,4-diones as an IN inhibitor scaffold.